Subscribe To Our Free NewsLetter
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Biomerica Receives CE Mark Approval
NEWPORT BEACH, CA--(MARKET WIRE)--Aug 7, 2007—Biomerica, Inc. (OTC BB:BMRA.OB - News) announced that it received CE mark approval for its 15-minute home diagnostic test for detecting Helicobacter pylori (H. pylori), a bacterium responsible for over 85% of ulcers. The one step test can now be marketed directly to consumers through drug stores in the European Union.
ADVERTISEMENT
Epidemiological studies have shown that the H. pylori infection is widespread, affecting over one billion people worldwide. It has been shown that nearly all duodenal ulcer patients and over 80% of stomach ulcer patients are infected with the bacterium. The disease affects both men and women. In addition to peptic ulcer disease, H. pylori infection has also been shown to be a significant risk factor for stomach cancer.
“This regulatory approval allows us to now sell our product to consumers throughout Europe,” said Zackary Irani, CEO Biomerica. “We are already in discussions with several significant distributors.”
Biomerica’s home test, which will be marketed under the trade name “FORTEL H.P. Ulcer Test,” is a simple fifteen-minute test that individuals can perform in the privacy of their own home. The test utilizes an advanced technology that requires only a drop of a patient’s blood.
It is estimated that the worldwide anti-ulcer market is over $9.5 billion. The FORTEL H.P. Ulcer Test is a part of BIOMERICA’s line of easy to use tests designed to detect diseases before they become catastrophic, incurable or costly to treat.
About Biomerica (OTC BB:BMRA.OB - News)
Biomerica, Inc. (http://www.biomerica.com) is a global medical technology company, based in Newport Beach, CA. The Company manufactures and markets advanced diagnostic products used at home, in hospitals, and in physicians’ offices for the early detection of medical conditions and diseases.
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking; such as statements relating to intended launch dates, sales potential, significant benefits, market size, growth of business, favorable positions, expansion, expected orders, leading market positions, anticipated future revenues or production volume of the Company, success of product and new product offerings. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, and accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. The potential risks and uncertainties include, among others, fluctuations in the Company’s operating results due to its business model and expansion plans, downturns in international and or national economies, the Company’s ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company’s dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.
Contact:
Contact :
Zackary Irani
Tel: 949-645-2111
--------------------------------------------------------------------------------
Source: Biomerica